Deepa Rangachari is an Oncology physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 26 publications with 539 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave # Shapiro9
Boston, MA 022155400
Telephone
617-667-1580Registry record last updated 7 Aug 2014.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.2%Kinase inhibitor53.2%Tagrisso86%Xalkori15%Part D<11 patientsBlood & clotting
21.2%Factor Xa inhibitor21.2%Eliquis100%Part D<11 patientsSensory organs
10.3%Corticosteroid10.3%Dexamethasone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14–skipping+ NSCLC.
Journal of Clinical Oncology
2025 - QIM25-234: Models and Outcomes of Multidisciplinary Clinics in Lung Cancer
Journal of the National Comprehensive Cancer Network
2025 - Needed leaders and leaders’ needs: The creation of a quality improvement and clinical operations pathway for heme/onc fellows.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”